LivaNova Consensus Price Target Increased by 17.90% to $107.33
The average one-year price target for LivaNova (NASDAQGS:LIVN) (DB:LIA) has been revised to $107.33 / share. This is an increase of 17.90% from the prior estimate of $91.03 dated October 30, 2026. These figures represent aggregate analyst targets compiled as of November 6, 2026, and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $75.75 to a high of $126.00 / share. The average price target represents an increase of 15.87% from the latest reported closing price of $92.63 / share on November 9, 2026. The target range widened, with the current target range width of $50.25 representing a +71.79% change from the prior width of $29.25. The current median target is $112.20, which increased from the prior median of $93.33.
As context, LivaNova reported its latest earnings on November 4, 2026. The company reported actual EPS of 1.23, which was above the estimate of 1.0784, representing a +14.06% surprise. Actual revenue reached $393,100,000.00, exceeding the estimate of $388,688,003.00 by +1.14%. In terms of stock performance, LivaNova's share price has experienced a one-week price change of +15.41% from a baseline close of $80.26 on November 2, 2026, and a one-month price change of +21.26% from a baseline close of $76.39 on October 9, 2026. The current mean target of $107.33 matches the observed twelve-month high mean from November 10, 2026, which is higher than the observed twelve-month low mean of $68.98 from November 17, 2025.
Recent analyst actions include Barclays maintaining an Overweight rating on November 9, 2026, Baird maintaining an Outperform rating on November 5, 2026, and Needham maintaining a Buy rating on November 4, 2026. The recommendation trend as of November 1, 2026, shows a total of 16 recommendations, consisting of 6 strong buy, 7 buy, and 3 hold recommendations, which is unchanged from the October 1, 2026 period.
Separate market context shows unusual listed-options activity for LivaNova on November 9, 2026. The total options volume reached 1,217, which is a 4.66x multiple of the average volume of 261. The put/call volume ratio was recorded at 0.01.
In the broader medical device and biotechnology space, LivaNova's peers showed varying target adjustments. While Medtronic's target revision remained flat, Abbott Laboratories and Boston Scientific saw downward revisions to their mean targets.
| Company | Target revision | Implied change |
|---|---|---|
| Medtronic | 0.00% | +4.23% |
| Abbott Laboratories | -0.09% | +10.16% |
| Boston Scientific | -3.14% | +25.66% |
LivaNova PLC, based in London, United Kingdom, operates predominantly in the medical device industry, focusing on manufacturing technologies for cardiac surgery and neuromodulation. Its key projects include Vagus Nerve Stimulation (VNS) therapy systems for treating epilepsy and depression, alongside cardiopulmonary products such as heart-lung machines and oxygenators.
Take Fintel with you. Download the Fintel app from the App Store or Google Play.
This story originally appeared on Fintel.